A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy

Int J Dermatol. 2014 Jan;53(1):e24-6. doi: 10.1111/j.1365-4632.2012.05483.x. Epub 2013 Mar 3.

Authors

Masahiro Kamata¹, Makoto Sugaya, Tomomitsu Miyagaki, Koya Sonoda, Yohei Ichimura, Hiroshi Mitsui, Shinichi Sato, Yasuhiko Kamikubo, Mineo Kurokawa

Affiliation

¹ Department of Dermatology, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan Department of Hematology and Oncology, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.

PMID: 23452101
DOI: 10.1111/j.1365-4632.2012.05483.x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Antigens, CD20 / metabolism*
Antineoplastic Agents / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cisplatin / administration & dosage
Cyclophosphamide / administration & dosage
Cytarabine / administration & dosage
Doxorubicin / administration & dosage
Etoposide / administration & dosage
Female
Humans
Lymphoma, T-Cell / drug therapy*
Lymphoma, T-Cell / metabolism
Methylprednisolone / administration & dosage
Prednisone / administration & dosage
Rituximab
T-Lymphocytes / metabolism*
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Agents
R-CHOP protocol
Cytarabine
Rituximab
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Prednisone
Methylprednisolone

Supplementary concepts

ESAP protocol